inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1inovmed-1498Research ArticleСтатьиНежелательные явления при лечении онкологических пациентов: нейротоксичность, васкулит, энцефалит и асептический менингитAdverse Events in the Treatment of Cancer Patients: Neurotoxicity, Vasculitis, Encephalitis, and Aseptic Meningitishttps://orcid.org/0000-0002-6845-5613ГвинджияС. Г.GvindzhiiaS. G.

Зяблова Елена Игоревна, д. м. н., доцент, заведующий кафедрой лучевой диагностики № 2; заведующий рентгеновским отделением

350086, Краснодар, ул. 1 мая, 167

Elena I. Zyablova, Dr. Sci. (Med.), Associate Professor Head of the Department of Radiation Diagnostics No. 2; Head of the X-ray Department; Chief Freelance Radiologist of the Ministry of Health of the Krasnodar Region

167 1 Maya St., Krasnodar, 350086

sariiagvindzhiia@gmail.comhttps://orcid.org/0009-0002-4743-7907КривицкаяЕ. Ю.KrivitskayaE. Yu.

Кривицкая Елена Юрьевна, врач-рентгенолог рентгеновского отделения; ассистент кафедры лучевой диагностики № 2

Краснодар

Elena Yu. Krivitskaya, Radiologist X-ray Department; Assistant, Department of Radiation Diagnostics No. 2

Krasnodar

https://orcid.org/0009-0000-3865-1421ЗябловаЕ. И.ZyablovaE. I.

Гвинджия Сария Гурамиевна, врач-рентгенолог рентгеновского отделения; ассистент кафедры лучевой диагностики № 2

Краснодар

Saria G. Gvindzhiia, Radiologist, X-ray Department; Assistant Professor, Department of Radiation Diagnostics No. 2

Krasnodar

ГБУЗ «НИИ – ККБ № 1 им. проф. С.В. Очаповского» Минздрава Краснодарского края; ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РФРоссияScientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical UniversityRussian Federation202630032026111-1Приложение1926Copyright © Гвинджия С.Г., Кривицкая Е.Ю., Зяблова Е.И., 20262026Гвинджия С.Г., Кривицкая Е.Ю., Зяблова Е.И.Gvindzhiia S.G., Krivitskaya E.Y., Zyablova E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/1498

Нежелательные явления со стороны центральной и периферической нервной системы на фоне проведения противоопухолевой терапии, включая лучевую терапию, иммунотерапию и химиотерапию, остаются сложной диагностической и клинической проблемой. Магнитно-резонансная томография является основным инструментом для оценки центральной нейротоксичности, поскольку помогает исключить опухолевую прогрессию, инфекционные и лекарственно-индуцированные изменения, а также сосудистые поражения.

В статье рассматриваются современные данные по патогенезу, клиническим проявлениям и типичным МРТ-паттернам основных церебральных осложнений лечения онкологических больных.

Adverse events affecting the central and peripheral nervous systems of associated with antitumor therapy, including radiation therapy, immunotherapy, and chemotherapy, remain a complex diagnostic and clinical challenge. Magnetic resonance imaging (MRI) is the main tool for assessing central neurotoxicity, allowing prevention of tumor progression, infectious and drug-induced changes, and vascular lesions. This article reviews current data on the pathogenesis, clinical manifestations, and typical MRI patterns of the main cerebral complications of cancer treatment.

нейротоксичностьасептический менингитэнцефалитваскулит ЦНСиммунотерапияICIsCAR-TМРТneurotoxicityaseptic meningitisencephalitisCNS vasculitisimmunotherapyICIsCAR-TMRIReferencesЗяблова Е.И. Визуализация побочных эффектов противоопухолевой терапии / Е.И. Зяблова. Краснодар: Кубанский государственный медицинский университет, 2025. – 156 с. – EDN YCEOIW.Зяблова Е.И. Визуализация побочных эффектов противоопухолевой терапии / Е.И. Зяблова. Краснодар: Кубанский государственный медицинский университет, 2025. – 156 с. – EDN YCEOIW.Lesley A Colvin. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? 2019 May; 160(Suppl 1): S1–S10. doi: 10.1097/j.pain.0000000000001540. PMCID: PMC6499732. EMSID: EMS81981. PMID: 31008843.Lesley A Colvin. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? 2019 May; 160(Suppl 1): S1–S10. doi: 10.1097/j.pain.0000000000001540. PMCID: PMC6499732. EMSID: EMS81981. PMID: 31008843.Jeremy H. Rees. The EBMT/EHA CAR-T Cell Handbook, Chapter 27: Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). February 7, 2022. URL: https://www.ncbi.nlm.nih.gov/books/NBK584157/.Jeremy H. Rees. The EBMT/EHA CAR-T Cell Handbook, Chapter 27: Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). February 7, 2022. URL: https://www.ncbi.nlm.nih.gov/books/NBK584157/.Pozzessere [et al.]. Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy / C. // A Comprehensive Imaging-Based Review. Cancers (Basel). 2024 Jul 19. No 16 (14). P. 2585. DOI: 10.3390/cancers16142585; PMID: 39061225; PMCID: PMC11274393.Pozzessere [et al.]. Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy / C. // A Comprehensive Imaging-Based Review. Cancers (Basel). 2024 Jul 19. No 16 (14). P. 2585. DOI: 10.3390/cancers16142585; PMID: 39061225; PMCID: PMC11274393.Stephen Klaus, Raluca Stanila. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) & New Onset Seizures with Overlapping MRI Sequelae. URL: https://aesnet.org/abstractslisting/immune-effector-cell-associated-neurotoxicity-syndromeicans-and-new-onset-seizures-with-overlapping-mri-sequelae.Stephen Klaus, Raluca Stanila. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) & New Onset Seizures with Overlapping MRI Sequelae. URL: https://aesnet.org/abstractslisting/immune-effector-cell-associated-neurotoxicity-syndromeicans-and-new-onset-seizures-with-overlapping-mri-sequelae.Gaillard F, Immune effector cell-associated neurotoxicity syndrome (ICANS). Case study, https://doi.org/10.53347/rID163107.Gaillard F, Immune effector cell-associated neurotoxicity syndrome (ICANS). Case study, https://doi.org/10.53347/rID163107.Gimber LH, Garland L, Krupinski EA, Chadaz TS, Schwenk M, Najafi B, Taljanovic MS. Diffusion Tensor Imaging of the Ankle as a Possible Predictor of Chemotherapy Induced Peripheral Neuropathy: Pilot Study. Curr Probl Diagn Radiol. 2019 MarApr;48(2):121-126. doi: 10.1067/j.cpradiol.2017.12.012. Epub 2018 Jan 6. PMID: 29397266.Gimber LH, Garland L, Krupinski EA, Chadaz TS, Schwenk M, Najafi B, Taljanovic MS. Diffusion Tensor Imaging of the Ankle as a Possible Predictor of Chemotherapy Induced Peripheral Neuropathy: Pilot Study. Curr Probl Diagn Radiol. 2019 MarApr;48(2):121-126. doi: 10.1067/j.cpradiol.2017.12.012. Epub 2018 Jan 6. PMID: 29397266.Buckley MW, Balaji Warner A, Brahmer J, Cappelli LC, Sharfman WH, Fuchs E, Kang H, Forde PM, Gladstone DE, Ambinder R, Kelly RJ, Lipson EJ, Gojo I, Lee EJ, Johnson TP, Saidha S, Llinas R, Ostrow LW, Naidoo J, Probasco JC. Immune-related encephalitis after immune checkpoint inhibitor therapy. Oncologist. 2025 Jan 17;30(1):oyae186. doi: 10.1093/oncolo/oyae186. PMID: 39066587; PMCID: PMC11783331.Buckley MW, Balaji Warner A, Brahmer J, Cappelli LC, Sharfman WH, Fuchs E, Kang H, Forde PM, Gladstone DE, Ambinder R, Kelly RJ, Lipson EJ, Gojo I, Lee EJ, Johnson TP, Saidha S, Llinas R, Ostrow LW, Naidoo J, Probasco JC. Immune-related encephalitis after immune checkpoint inhibitor therapy. Oncologist. 2025 Jan 17;30(1):oyae186. doi: 10.1093/oncolo/oyae186. PMID: 39066587; PMCID: PMC11783331.Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez-Villacampa MM, Nadal E, Bruna J. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. JAMA Neurol. 2021 Jul 1;78(7):864-873. doi: 10.1001/jamaneurol.2021.0249. PMID: 33720308.Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez-Villacampa MM, Nadal E, Bruna J. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. JAMA Neurol. 2021 Jul 1;78(7):864-873. doi: 10.1001/jamaneurol.2021.0249. PMID: 33720308.Zhao Z, Zhang C, Zhou L, Dong P, Shi L. Immune Checkpoint Inhibitors and Neurotoxicity. Curr Neuropharmacol. 2021;19(8):1246-1263. doi: 10.2174/1570159X196662012301512 24. PMID: 33380303; PMCID: PMC8719293.Zhao Z, Zhang C, Zhou L, Dong P, Shi L. Immune Checkpoint Inhibitors and Neurotoxicity. Curr Neuropharmacol. 2021;19(8):1246-1263. doi: 10.2174/1570159X196662012301512 24. PMID: 33380303; PMCID: PMC8719293.Melissa Yelehe-Okouma, Julie Czmil-Garon, Elise Pape, Nadine Petitpain, Pierre Gillet. Drug-induced aseptic meningitis: a mini-review. 24 January 2018.Melissa Yelehe-Okouma, Julie Czmil-Garon, Elise Pape, Nadine Petitpain, Pierre Gillet. Drug-induced aseptic meningitis: a mini-review. 24 January 2018.Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. J Neurooncol. 2022 May;157(3):533-550. doi: 10.1007/s11060-022-03997-7. Epub 2022 Apr 13. PMID: 35416575; PMCID: PMC9458695.Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. J Neurooncol. 2022 May;157(3):533-550. doi: 10.1007/s11060-022-03997-7. Epub 2022 Apr 13. PMID: 35416575; PMCID: PMC9458695.Feng J, Ross L, Ontaneda D. Pembrolizumab-Induced CNS Vasculitis: Neurologic Adverse Events Due to Checkpoint Inhibitors. Neurol Clin Pract. 2021 Feb;11(1):e30-e32. doi: 10.1212/CPJ.0000000000000768. PMID: 33968488; PMCID: PMC8101305.Feng J, Ross L, Ontaneda D. Pembrolizumab-Induced CNS Vasculitis: Neurologic Adverse Events Due to Checkpoint Inhibitors. Neurol Clin Pract. 2021 Feb;11(1):e30-e32. doi: 10.1212/CPJ.0000000000000768. PMID: 33968488; PMCID: PMC8101305.Crout TM, Lennep DS, Kishore S, Majithia V. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Curr Rheumatol Rep. 2019 May 21;21(6):28. doi: 10.1007/s11926-019-0828-7. PMID: 31115712.Crout TM, Lennep DS, Kishore S, Majithia V. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Curr Rheumatol Rep. 2019 May 21;21(6):28. doi: 10.1007/s11926-019-0828-7. PMID: 31115712.

The authors declare that there are no conflicts of interest present.